Riluzole enhances the antiseizure action of conventional antiepileptic drugs against pentetrazole-induced convulsions in mice

Polish Journal of Pharmacology

Volumn 56, Issue 2, 2004, Pages 187-193

  Borowicz, Kinga K ^a   Sekowski, Andrzej ^a   Drelewska, Edyta ^a   Czuczwar, Stanisław J ^a,b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b INSTITUTE OF AGRICULTURAL MEDICINE   (Poland)

Author keywords

Antiepileptic drugs; Pentetrazole induced seizures; Riluzole

Indexed keywords

1 (4 AMINOPHENYL) 4 METHYL 7,8 METHYLENEDIOXY 5H 2,3 BENZODIAZEPINE; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 4 (3 PHOSPHONOALLYL) 2 PIPERAZINECARBOXYLIC ACID; 6 NITRO 7 SULFAMOYLBENZO[F]QUINOXALINE 2,3 DIONE; ANTICONVULSIVE AGENT; BICUCULLINE; CARBAMAZEPINE; CGP 395551; CLONAZEPAM; DIZOCILPINE; ETHOSUXIMIDE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; PENTETRAZOLE; PHENOBARBITAL; PHENYTOIN; PICROTOXIN; RILUZOLE; TALAMPANEL; UNCLASSIFIED DRUG; VALPROIC ACID;

ABSENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; CONTROLLED STUDY; CONVULSION; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; MALE; MEMORY DISORDER; MOUSE; MYOCLONUS EPILEPSY; NONHUMAN; POSTSYNAPTIC MEMBRANE; PRESYNAPTIC NERVE; SEIZURE; ANIMAL; AVOIDANCE BEHAVIOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DRUG EFFECT; PHYSIOLOGY;

ANIMALS; ANTICONVULSANTS; AVOIDANCE LEARNING; DRUG SYNERGISM; MALE; MICE; PENTYLENETETRAZOLE; RILUZOLE; SEIZURES;

EID: 3142703697     PISSN: 12306002     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Boissier J-R, Tardy J, Diverres J-C: Une nouvelle méthode simple pour explorer l'action 'tranquillisante': le test de la cheminée. Med Exp (Basel), 1960, 3, 81-84.
2. Borowicz KK, Gasior M, Kleinrok Z, Czuczwar SJ: The non-competitive AMPA/kainate receptor antagonist, GYKI 52466, potentiates the anticonvulsant activity of conventional antiepileptics. Eur J Pharmacol, 1995, 281, 319-325.
3. Borowicz KK, Piskorska B, Łuszczki J, Czuczwar SJ: Influence of SIB 1893, a selective mGluR5 receptor antagonist, on the anticonvulsant activity of conventional antiepileptic drugs in two models of experimental epilepsy. Pol J Pharmacol, 2003, 55, 735-740.
4. Bracket RL, Pouw B, Blyden JF, Nour M, Matsumoto RR: Prevention of cocaine-induced convulsions and lethality in mice: effectiveness of targeting different sites on the NMDA receptor complex. Neuropharmacology, 2000, 39, 407-418.
5. Bryson HM, Fulton B, Benfield P: Riluzole. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in amyotrophic lateral sclerosis. Drugs, 2000, 52, 549-563.
6. Centonze D, Calabresi P, Pisani A, Marinelli S, Marfia GA, Bernardi G: Electrophysiology of the neuroprotective agent riluzole on striatal spiny neurons. Neuropharmacology, 1998, 37, 1063-1070.
7. Czechowska G, Dziki M, Pietrasiewicz T, Kleinrok Z, Turski WA, Czuczwar SJ: Competitive antagonists of NMDA receptors, CGP 37849 and CGP 39551, enhance the anticonvulsant activity of valproate against electroconvulsions in mice. Eur J Pharmacol, 1993, 232, 59-64.
8. Czuczwar SJ, Kamiński R, Gasior M, Kozicka M, Zawadzki A, Kleinrok Z: LY 300164, a novel non-NMDA receptor antagonist, potentiates the anticonvulsive activity of antiepileptic drugs. In: 4th Congress of the European Society for Clinical Neuropharmacology, Eilat, Israel, December 1-4, 1997. Ed. Korczyn AD, Monduzzi Editore, Bologna, 1998, 35-39.
9. Czuczwar SJ, Świader M, Kuźniar H, Gasior M, Kleinrok Z: LY 300164, a novel antagonist of AMPA/kainate receptors, potentiates the anticonvulsive activity of antiepileptic drugs. Eur J Pharmacol, 1998, 359, 103-109.
10. Czuczwar SJ, Turski WA, Kleinrok Z: Interaction of calcium channel blockers and excitatory amino acid antagonists with conventional antiepileptic drugs. CNS Drug Rev, 1996, 2, 452-467.
11. De Sarro G, Siniscalchi A, Ferreri G, Gallelli L, De Sarro A: NMDA and AMPA/kainate receptors are involved in the anticonvulsant activity of riluzole in DBA2/mice. Eur J Pharmacol, 2000, 408, 25-34.
12. Duprat F, Lesage F, Patel AJ, Fink M, Romey G, Lazdunski M: The neuroprotective agent riluzole activates the two P domain K(+) channels TREK-1 and TRAAK. Mol Pharmacol, 2000, 57, 906-912.
13. Herbert T, Drapeau P, Pradier L, Dunn RJ: Block of the rat brain IIA sodium channel alpha subunit by the neuroprotective drug riluzole. Mol Pharmacol, 1994, 45, 1055-1060.
14. Kanthasamy AG, Yun RJ, Nguyen B, Truong DD: Effect of riluzole on the neurological and neuropathological changes in an animal model of cardiac arrest-induced movement disorder. J Pharmacol Exp Ther, 1999, 288, 1340-1348.
15. Kretschmer BD, Kratzer U, Schmidt WJ: Riluzole, a glutamate release inhibitor, and motor behavior. Naunyn Schmiedebergs Arch Pharmacol, 1998, 358, 181-190.
16. Kwon JY, Bacher A, Zornow MH: Riluzole does not attenuate increases in hippocampal glutamate concentrations in a rabbit model of repeated transient global cerebral ischemia. Anesth Analg, 1998, 86, 128-133.
17. Litchfield JT, Wilcoxon F: A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther, 1949, 96, 99-113.
18. Löscher W, Schmidt D: Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res, 1988, 2, 145-181.
19. Łuszczki J, Borowicz KK, Czuczwar SJ: SIB 1893 possesses pro- and anticonvulsive activity in the electroshock seizure threshold test in mice. Pol J Pharmacol, 2002, 54, 517-520.
20. Malgouris C, Daniel M, Doble A: Neuroprotective effects of riluzole on N-methyl-D-aspartate- or veratridine-induced neurotoxicity in rat hippocampal slices. Neurosci Lett, 1994, 177, 95-99.
21. Mantz J, Laudenbach V, Lecharny JB, Henzel D, Desmonts JM: Riluzole, a novel antiglutamate, blocks GABA uptake by striatal synaptosomes. Eur J Pharmacol, 1994, 257, R7-R8.
22. Mary V, Wahl F, Stutzman JM: Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers od glutamatergic neurotransmission. Neurosci Lett, 1995, 201, 92-96.
23. Mizoule J, Meldrum B, Mazadier M, Croucher M, Ollat C, Uzan A, Legrand JJ et al.: 2-Amino-6-trifluoro-methoxy-benzothiazole, a possible antagonist of excitatory amino acid neurotransmission. I. Anticonvulsant properties. Neuropharmacology, 1985, 24, 767-773.
24. Parsons CG, Danysz W, Quack G: Glutamate in CNS disorders as a target for drug development: an update. Drugs News Perspect, 1998, 11, 523-569.
25. Pietrasiewicz T, Czechowska G, Dziki M, Turski WA, Kleinrok Z, Czuczwar SJ: Competitive NMDA receptor antagonists enhance the antielectroshock activity of various antiepileptics. Eur J Pharmacol, 1993, 250, 1-7.
26. Samuel D, Blin O, Dusticier N, Nieoullon A: Effects of riluzole (2-amino-6-trifluoromethoxy benzothiazole) on striatal neurochemical markers in the rat, with special reference to the dopamine, choline, GABA and glutamate synaptosomal high affinity uptake systems. Fundam Clin Pharmacol, 1992, 6, 177-184.
27. Schmutz M, Portet C, Jeker A, Klebs A, Vassout A, Allgeier H, Heckendorn R et al.: The competitive NMDA receptor antagonists CGP 37849 and CGP 39551 are potent orally active anticonvulsants in rodents. Naunyn Schmiedebergs Arch Pharmacol, 1990, 342, 61-66.
28. Sindou P, Couratier P, Esclaire F, Yardin C, Bousseau A, Hugon J: Prevention of HIV coat protein (gp 120) toxicity in cortical cell cultures by riluzole. J Neurol Sci, 1994, 126, 133-137.
29. Steppuhn KG, Turski L: Modulation of the seizure threshold for excitatory amino acid in mice by antiepileptic drugs and chemoconvulsants. J Pharmacol Exp Ther, 1993, 265, 1063-1070.
30. Stutzmann JM, Bohme GA, Gandolfo G, Gottesmann C, Lafforgue J, Blanchard JC, Laduron PM et al.: Riluzole prevents hyperexcitability produced by the mast cell degranulating peptide and dendrotoxin I in the rat. Eur J Pharmacol, 1991, 193, 223-229.
31. Umemiya M, Berger AJ: Inhibition by riluzole of glycinergic postsynaptic currents in rat hypoglossal motoneurones. Br J Pharmacol, 1995, 116, 3227-3230.
32. Urbańska EM, Dziki M, Kleinrok Z, Czuczwar SJ, Turski WA: Influence of MK-801 on the anticonvulsant activity of antiepileptics. Eur J Pharmacol, 1991, 200, 277-282.
33. Venault P, Chapoutier G, De Carvalho LP, Simiand J, Morre M, Dodd RH, Rossier J: Benzodiazepines impair and beta-carbolines enhance performance in learning and memory tasks. Nature, 1986, 321, 864-866.
34. Yoshida M, Noguchi E, Tsuru N, Ohkoshi N: Effect of riluzole on the acquisition and expression of amygdala kindling. Epilepsy Res, 2001, 46, 101-109.
35. Zona C, Siniscalchi A, Mercuri NB, Bernardi G: Riluzole interacts with voltage-activated sodium and potassium currents in cultured rat cortical neurons. Neuroscience, 1998, 85, 931-938.
36. Zarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ: 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock in mice. Neuropharmacology, 1993, 32, 895-900.
37. Zarnowski T, Kleinrok Z, Turski WA, Czuczwar SJ: The competitive NMDA antagonist, D-CPP-ene, potentiates the anticonvulsant activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. Neuropharmacology, 1994, 33, 619-624.